Traws Pharma, Inc.
TRAW
$1.41
-$0.12-7.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -1.75% | 0.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -1.75% | 0.00% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -1.75% | 0.00% | |||
| SG&A Expenses | -0.11% | 76.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -37.93% | 44.64% | |||
| Operating Income | 38.17% | -45.07% | |||
| Income Before Tax | -253.06% | 93.12% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -253.06% | 93.12% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -253.06% | 93.12% | |||
| EBIT | 38.17% | -45.07% | |||
| EBITDA | 38.18% | -45.14% | |||
| EPS Basic | 401.84% | 92.75% | |||
| Normalized Basic EPS | -10.24% | -57.13% | |||
| EPS Diluted | 401.84% | 92.75% | |||
| Normalized Diluted EPS | -10.24% | -57.13% | |||
| Average Basic Shares Outstanding | 220.27% | -5.03% | |||
| Average Diluted Shares Outstanding | 220.27% | -5.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||